Abstract:Among patients with HCC who received immunotherapy, lower NLR, and MLR at baseline in overall patients were significantly associated with better disease control and more favorable survival outcomes (both OS and PFS), and lower PLR was significantly associated with longer PFS. The findings of this research may offer useful hints for an optimized selection of patients with liver cancer who may benefit more from immunotherapy. Background Peripheral blood immunomarkers are associated with prognosis in patients with solid tumors receiving chemotherapy or immunotherapy. In this study, the associations of circulating neutrophil‐to‐lymphocyte ratio (NLR), monocyte‐to‐lymphocyte ratio (MLR), and platelet‐to‐lymphocyte ratio (PLR), as well as their dynamic changes were investigated in relation to the efficacy of immunotherapy in patients with primary liver cancer. Methods Comparisons were made between NLR, MLR, and PLR among individuals exhibiting disease control (defined as the best response of partial response [PR] or stable disease [SD]) and those with progressive disease (PD). Additionally, disease control rate (DCR), overall survival (OS), and progression‐free survival (PFS) were compared between individuals with different NLR, MLR, and PLR levels before initiating palliative immunotherapy. Furthermore, comparisons were made between patients with different alterations in the ratios at the second cycle of immunotherapy compared to baseline. These analyses were performed using univariate and multivariate approaches. A total of 119 Chinese patients with liver cancer who underwent immunotherapy were included in this study, which focused on hepatocellular carcinoma (HCC). Results In cases with HCC (n = 104), the cutoffs of NLR, MLR, and PLR to differentiate treatment responders from nonresponders were 3.38, 0.28, and 227.18, respectively. Patients with the best response of PR or SD had significantly lower NLR and MLR. Patients with NLR <3.38 and those with MLR <0.28 significantly had longer OS and PFS than their counterparts, and those with PLR <227.18 had significantly longer PFS, both in overall patients and in various patient subgroups. Lower NLR, MLR, or PLR was associated with earlier BCLC stage, fewer metastatic sites, less frequent extrahepatic metastasis, or better performance status. For individuals who had an unfavorable baseline NLR ≥3.38, MLR ≥0.28, or a favorable baseline PLR <227.18 prior to first immunotherapy, a decrease in NLR, MLR, or PLR at Cycle 2 of immunotherapy was significantly associated with a higher DCR. Conclusions Among patients with HCC who received immunotherapy, lower NLR, and MLR at baseline in overall patients were significantly associated with better disease control and more favorable survival outcomes (both OS and PFS), and lower PLR was significantly associated with longer PFS. The findings of this research may offer useful hints foranoptimized selection of patients with liver cancer who may benefit more from immunotherapy.

Immune factor GMCSF, NLRP3 and TLR4 expression in the hepatic celluler cancer

Expression of TIGIT/CD155 and Correlations with Clinical Pathological Features in Human Hepatocellular Carcinoma

The expression significance of caspase-3 in the tissne of liver cancer and the relationship with HBV infection

Expressions of Inflammation-Associated Factors IL-1β, TGF-β and MCP-1 in Human Hepatocellular Carcinoma

The expression levels of transcription factors T-bet, GATA-3, RORγt and FOXP3 in peripheral blood lymphocyte (PBL) of patients with liver cancer and their significance.

Expression of Multi-Drug Resistance-Related Genes MDR3 and MRP As Prognostic Factors in Clinical Liver Cancer Patients.

Associations of circulating immunomarkers with the efficacy of immunotherapy for primary hepatic carcinoma

The Diagnostic Value of Chemokine/Chemokine Receptor Pairs in Hepatocellular Carcinoma and Colorectal Liver Metastasis.

Effect of CD44 gene polymorphism on infiltration of local T cell subsets in primary liver cancer tissue

The Expression of TPO and GM-CSF in the Marrow Fluid and the Relations with Peripheral Blood Cells of Liver Cirrhosis Patients

Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma

Expression and significance of nuclear factor of activated T-cells cytoplasmic 1 in hepatocellular carcinoma

[Expression and clinical significance of chemokine CXCL10 and its receptor CXCR3 in hepatocellular carcinoma].

Expression and clinical significance of NLRC5 in hepatocellular carcinoma

The in Situ Analysis of Cytokine Mrna Expression in Immunological Microenvironment about Non-Small Cell Lung Cancer

Initial Study on the Expression of SPP-1,GDF-15 and CXCL-1 in Human Small Hepatocellular Carcinoma

The Expression of Nuclear Factor of Activated T Cells in Hepatocellular Carcinoma and Its Relationship with Clinicopathologic Factors

Role of Chronic Inflammation in Cancers of the Gastrointestinal System and the Liver: Where We Are Now.

Identification of Therapeutic Targets and Prognostic Biomarkers Among Chemokine (C-C Motif) Ligands in the Liver Hepatocellular Carcinoma Microenvironment

Identification of CFHR4 as a Potential Prognosis Biomarker Associated With lmmune Infiltrates in Hepatocellular Carcinoma

Expressions of Zinc Finger Protein A20, NF-κB P65 Protein, and P-glycoprotein in Primary Hepatocellular Carcinoma